---
schema_version: "secwatch.filing_event.v1"
accession: "0001837607-24-000077"
form_type: "8-K"
ticker: "AEON"
cik: "0001837607"
company_name: "AEON Biopharma, Inc."
filed_at: "2024-07-09T23:59:59+00:00"
generated_at: "2026-05-31T22:39:02.604284+00:00"
event_type: "other_material"
sentiment: "neutral"
materiality_score: 0.75
calibrated_materiality_score: 0.75
confidence: "high"
source: SEC EDGAR
---

# AEON Biopharma shifts ABP-450 to biosimilar pathway targeting BOTOX; plans pivotal study in cervical dystonia

## Summary
- ABP-450 will pursue 351(k) biosimilar pathway using AbbVie's BOTOX as reference product.
- Company plans a single pivotal Phase 3 comparative study in cervical dystonia.
- Successful Phase 3 could support biosimilar determination for up to 8 therapeutic indications.
- Biosimilar Initial Advisory Meeting with FDA scheduled for Q3 2024.

## SEC filing metadata
- accession: 0001837607-24-000077
- form_type: 8-K
- ticker: AEON
- cik: 0001837607
- company_name: AEON Biopharma, Inc.
- filed_at: 2024-07-09T23:59:59+00:00
- event_type: other_material
- sentiment: neutral
- materiality_score: 0.75
- calibrated_materiality_score: 0.75
- confidence: high
- sec_items: 8.01
- EDGAR index: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000077/0001837607-24-000077-index.htm
- EDGAR primary document: https://www.sec.gov/Archives/edgar/data/1837607/000183760724000077/aeon-20240709x8k.htm

## Machine-readable alternates
- HTML: https://secwatch.observer/filing/0001837607-24-000077
- JSON: https://secwatch.observer/filing/0001837607-24-000077.json
- Plain text: https://secwatch.observer/filing/0001837607-24-000077.txt

This AI-assisted summary is a reading aid. Review the linked SEC EDGAR filing before relying on any specific claim.